Former Meta Executive Accuses Company of Compromising U.S. Security

Two biotech penny stocks, Solid Biosciences (SLDB) and Foghorn Therapeutics (FHTX), are attracting significant attention from analysts predicting substantial upside potential. Solid Biosciences, focused on gene therapies for severe diseases like Duchenne muscular dystrophy, has a price target of $16, suggesting a potential rise of approximately 450% from its current price of $2.88, according to Truist analyst Joon Lee. The company is anticipating early results from its SGT-003 trials, which are expected to drive investor excitement.
Foghorn Therapeutics, trading at $4.75, is targeting chromatin regulation in cancer treatment and has received a "Strong Buy" consensus from analysts with a price target of $10.25. B. Riley analyst Kalpit Patel advises that recent stock weakness presents a buying opportunity, given the promising outlook for its FHD-909 clinical trials.
Both stocks are seen as showcasing the potential in smaller, lesser-known biotech companies that could yield significant rewards amid rising interest in innovative therapies.